Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment?

被引：1
|
作者：
Altundag, Kadri [1 ]
机构：
[1] MKA Breast Canc Clin, Ankara 06800, Turkey
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2020年 / 181卷 / 03期
关键词：
D O I：
10.1007/s10549-020-05649-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：691 / 691
页数：1
相关论文
共 19 条
  • [1] Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment?
    Kadri Altundag
    Breast Cancer Research and Treatment, 2020, 181 : 691 - 691
  • [2] Absolute lymphocyte count (ALC) is a predictor of eribulin benefit in advanced or metastatic breast cancer (MBC)
    Cortes, Javier
    Manuel Perez-Garcia, Jose
    Nomoto, Kenichi
    Alexis, Karenza
    Saito, Kenichi
    Yoshimura, Yuta
    Muramoto, Kenzo
    Miyoshi, Yasuo
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
    Ogiya, Rin
    Niikura, Naoki
    Kumaki, Nobue
    Bianchini, Giampaolo
    Kitano, Shigehisa
    Iwamoto, Takayuki
    Hayashi, Naoki
    Yokoyama, Kozue
    Oshitanai, Risa
    Terao, Mayako
    Morioka, Toru
    Tsuda, Banri
    Okamura, Takuho
    Saito, Yuki
    Suzuki, Yasuhiro
    Tokuda, Yutaka
    CANCER SCIENCE, 2016, 107 (12) : 1730 - 1735
  • [4] Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
    Ogiya, Rin
    Kumaki, Nobue
    Bianchini, Giampaolo
    Iwamoto, Takayuki
    Hayashi, Naoki
    Tanaka, Toshiya
    Niikura, Naoki
    Tokuda, Yutaka
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer
    Goto, Wataru
    Kashiwagi, Shinichiro
    Takada, Koji
    Asano, Yuka
    Morisaki, Tamami
    Shibutani, Masatsune
    Tanaka, Hiroaki
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2022, 42 (02) : 939 - 946
  • [6] The association between tumor-infiltrating lymphocytes (TIL) and focal adhesion kinase (FAK) in breast cancer patients
    Indrakusuma, A.
    Sadeva, I.
    Wulandari, P.
    Supadmanaba, I.
    Wihandani, D.
    Adiputra, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S1391 - S1391
  • [7] Correlation of Tumor-infiltrating lymphocytes with clinicopathological features and treatment outcomes in non-metastatic breast cancer patients
    Hegazy, Neamat Elsayed
    Motal, Haitham Mohsen Abdel
    Tayel, Hanan Yehia
    Ismail, Abdelsalam A.
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502
    Stover, Daniel G.
    Salgado, Roberto
    Savenkov, Oleksander
    Ballman, Karla
    Mayer, Erica L.
    Magbanua, Mark Jesus M.
    Loi, Sherene
    Vater, Mark
    Glover, Kristyn
    Watson, Mark
    Wen, Yujia
    Symmans, W. Fraser
    Perou, Charles
    Carey, Lisa A.
    Partridge, Ann H.
    Rugo, Hope S.
    NPJ BREAST CANCER, 2024, 10 (01)
  • [9] Association of baseline tumor-infiltrating lymphocytes and cell-cycle regulation markers on prognosis and mortality in patients with advanced breast cancer according to tumor characteristics and treatment type
    Vuoti, Sauli
    Saari, Minna
    Narasimha, Kumar
    Reinikainen, Kai
    CANCER RESEARCH, 2023, 83 (05)
  • [10] A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience
    Watanabe, J.
    Saito, M.
    Horimoto, Y.
    Nakamoto, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 211 - 220
12